C-VGB3
C-VGB3 is a selective vascular endothelial growth factor receptor 2 (VEGFR2) antagonist, which inhibits VEGFR2-mediated PI3K/AKT/mTOR and PLCγ/ERK1/2 signaling pathways. C-VGB3 binds to the extracellular domain of VEGFR2, blocking ligand-receptor interaction and inducing apoptosis in endothelial and tumor cells through both intrinsic (involving Bcl2 family and caspases) and extrinsic (death receptor-mediated) pathways. C-VGB3 is promising for research of angiogenesis-related cancers, such as breast cancer.
For research use only. We do not sell to patients.
- Formula: C43H67N13O17S2
- Molecular Weight:1102.20
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All VEGFR Isoforms
More
Biological Activity
|
VEGFR2 |
Chemical Information
-
Molecular Weight 1102.20
-
Formula C43H67N13O17S2
-
Sequence
Glu-Cys-Arg-Pro-Pro-Asp-Asp-Gly-Leu-Cys (Disulfide bridge: Cys2-Cys10)
-
Sequence Shortening
ECRPPDDGLC (Disulfide bridge: Cys2-Cys10)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Namjoo M, et al. A VEGFB-Based Peptidomimetic Inhibits VEGFR2-Mediated PI3K/Akt/mTOR and PLCγ/ERK Signaling and Elicits Apoptotic, Antiangiogenic, and Antitumor Activities. Pharmaceuticals (Basel). 2023 Jun 20;16(6):906. [Content Brief]
[2]. Sadremomtaz A, et al. Molecular docking, synthesis and biological evaluation of Vascular Endothelial Growth Factor (VEGF) B based peptide as antiangiogenic agent targeting the second domain of the Vascular Endothelial Growth Factor Receptor 1 (VEGFR1D2) for anticancer application. Signal Transduct Target Ther. 2020 Jun 5;5(1):76. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)